دورية أكاديمية
أعرض في EDS

Incidence of venous thromboembolism and bleeding in patients with malignant central nervous system neoplasm: Systematic review and meta-analysis.

التفاصيل البيبلوغرافية
العنوان: Incidence of venous thromboembolism and bleeding in patients with malignant central nervous system neoplasm: Systematic review and meta-analysis.
المؤلفون: Veiga VC; BP-A Beneficência Portuguesa de São Paulo, São Paulo, Brasil., Peres SV; BP-A Beneficência Portuguesa de São Paulo, São Paulo, Brasil., Ostolin TLVDP; BP-A Beneficência Portuguesa de São Paulo, São Paulo, Brasil., Moraes FR; BP-A Beneficência Portuguesa de São Paulo, São Paulo, Brasil., Belucci TR; BP-A Beneficência Portuguesa de São Paulo, São Paulo, Brasil., Clara CA; Hospital do Câncer de Barretos, São Paulo, Brasil., Cavalcanti AB; HCor-Research Institute, São Paulo, Brasil., Chaddad-Neto FEA; Universidade Federal de São Paulo, São Paulo, Brasil., Batistella GNR; HCor-Research Institute, São Paulo, Brasil., Neville IS; Instituto do Câncer de São Paulo, São Paulo, Brasil., Baeta AM; BP-A Beneficência Portuguesa de São Paulo, São Paulo, Brasil., Yamada CAF; BP-A Beneficência Portuguesa de São Paulo, São Paulo, Brasil.
مؤلفون مشاركون: TROMBOGLIO Study Group
المصدر: PloS one [PLoS One] 2024 Jun 20; Vol. 19 (6), pp. e0304682. Date of Electronic Publication: 2024 Jun 20 (Print Publication: 2024).
نوع المنشور: Journal Article; Systematic Review; Meta-Analysis
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Venous Thromboembolism*/epidemiology , Venous Thromboembolism*/etiology , Central Nervous System Neoplasms*/epidemiology , Central Nervous System Neoplasms*/complications , Hemorrhage*/epidemiology, Humans ; Incidence ; Male ; Female
مستخلص: Central nervous system (CNS) malignant neoplasms may lead to venous thromboembolism (VTE) and bleeding, which result in rehospitalization, morbidity and mortality. We aimed to assess the incidence of VTE and bleeding in this population.
Methods: This systematic review and meta-analysis (PROSPERO CRD42023423949) were based on a standardized search of PubMed, Virtual Health Library and Cochrane (n = 1653) in July 2023. After duplicate removal, data screening and collection were conducted by independent reviewers. The combined rates and 95% confidence intervals for the incidence of VTE and bleeding were calculated using the random effects model with double arcsine transformation. Subgroup analyses were performed based on sex, age, income, and type of tumor. Heterogeneity was calculated using Cochran's Q test and I2 statistics. Egger's test and funnel graphs were used to assess publication bias.
Results: Only 36 studies were included, mainly retrospective cohorts (n = 30, 83.3%) from North America (n = 20). Most studies included were published in high-income countries. The sample size of studies varied between 34 and 21,384 adult patients, mostly based on gliomas (n = 30,045). For overall malignant primary CNS neoplasm, the pooled incidence was 13.68% (95%CI 9.79; 18.79) and 11.60% (95%CI 6.16; 18.41) for VTE and bleeding, respectively. The subgroup with elderly people aged 60 or over had the highest incidence of VTE (32.27% - 95%CI 14.40;53.31). The studies presented few biases, being mostly high quality. Despite some variability among the studies, we observed consistent results by performing sensitivity analysis, which highlight the robustness of our findings.
Conclusions: Our study showed variability in the pooled incidence for both overall events and subgroup analyses. It was highlighted that individuals over 60 years old or diagnosed with GBM had a higher pooled incidence of VTE among those with overall CNS malignancies. It is important to note that the results of this meta-analysis refer mainly to studies carried out in high-income countries. This highlights the need for additional research in Latin America, and low- and middle-income countries.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Veiga et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
References: Thromb Res. 2023 Apr;224:21-31. (PMID: 36805800)
World Neurosurg. 2019 May;125:e189-e197. (PMID: 30684707)
Curr Oncol. 2023 May 12;30(5):4946-4956. (PMID: 37232831)
Thromb Res. 2013 Feb;131(2):162-5. (PMID: 23084660)
Support Care Cancer. 2023 Jun 3;31(6):373. (PMID: 37269357)
J Neurosurg. 2013 Mar;118(3):505-9. (PMID: 23240698)
Neurooncol Pract. 2016 Jun;3(2):87-96. (PMID: 31386010)
Neuro Oncol. 2014 Dec;16(12):1645-51. (PMID: 24987133)
Neuro Oncol. 2022 Mar 12;24(3):455-464. (PMID: 34383073)
Clin Neurol Neurosurg. 2021 Nov;210:106998. (PMID: 34739883)
Neurochirurgie. 2018 Jun;64(3):161-165. (PMID: 29859696)
Eur J Neurol. 2022 Aug;29(8):2386-2397. (PMID: 35545894)
Thromb Res. 2016 Jan;137:58-63. (PMID: 26610747)
Neurology. 2021 Feb 16;96(7):e1063-e1069. (PMID: 33361259)
BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
J Neurooncol. 2022 Feb;156(3):541-549. (PMID: 35094201)
Neurocrit Care. 2016 Feb;24(1):47-60. (PMID: 26646118)
J Thromb Haemost. 2010 Feb;8(2):221-7. (PMID: 19912518)
Blood Adv. 2021 Feb 23;5(4):927-974. (PMID: 33570602)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96. (PMID: 33123732)
Blood. 2021 Apr 8;137(14):1959-1969. (PMID: 33171494)
Brain Behav. 2020 Jun;10(6):e01638. (PMID: 32314875)
Rejuvenation Res. 2013 Jun;16(3):224-31. (PMID: 23521603)
Arch Public Health. 2022 Sep 17;80(1):209. (PMID: 36115969)
Acta Neuropathol. 2016 Dec;132(6):917-930. (PMID: 27664011)
J Clin Oncol. 2011 May 20;29(15):2099-103. (PMID: 21464402)
Blood. 2020 Sep 17;136(12):1433-1441. (PMID: 32396939)
Neuro Oncol. 2023 Aug 3;25(8):1381-1394. (PMID: 37100086)
J Neurooncol. 2015 Aug;124(1):137-46. (PMID: 26033544)
Front Neurol. 2023 Apr 18;14:1108596. (PMID: 37144008)
Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):774-83. (PMID: 24608188)
Clin Microbiol Infect. 2014 Feb;20(2):123-9. (PMID: 24320992)
J Neurooncol. 2016 Dec;130(3):561-570. (PMID: 27591773)
J Neurooncol. 2013 Jun;113(2):293-303. (PMID: 23543244)
Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):953-66. (PMID: 24700176)
J Thromb Haemost. 2010 Jan;8(1):202-4. (PMID: 19878532)
JAMA. 2023 Feb 21;329(7):574-587. (PMID: 36809318)
Thromb Res. 2020 Dec;196:245-250. (PMID: 32919179)
J Neurol. 2013 Mar;260(3):847-55. (PMID: 23104124)
Pharmacotherapy. 2019 Sep;39(9):921-928. (PMID: 31332810)
Neurosurgery. 2018 Feb 1;82(2):142-154. (PMID: 28402497)
Lancet Reg Health Am. 2021 Aug 17;2:100042. (PMID: 36779037)
Cureus. 2018 May 23;10(5):e2678. (PMID: 30050733)
J Thromb Thrombolysis. 2017 Oct;44(3):392-398. (PMID: 28836150)
J Neurooncol. 2015 Sep;124(2):299-305. (PMID: 26100546)
J Thromb Haemost. 2019 Jan;17(1):72-76. (PMID: 30450803)
Neuro Oncol. 2022 Jun 1;24(6):964-973. (PMID: 34647594)
Gynecol Oncol. 2021 Apr;161(1):304-313. (PMID: 33563489)
Blood. 2017 Jun 22;129(25):3379-3385. (PMID: 28468796)
J Thromb Haemost. 2020 Nov;18(11):2852-2860. (PMID: 32767653)
Cureus. 2018 Sep 10;10(9):e3277. (PMID: 30443448)
Oncologist. 2019 Apr;24(4):529-536. (PMID: 30049883)
J Clin Oncol. 2006 Jan 20;24(3):484-90. (PMID: 16421425)
J Neurooncol. 2017 Jul;133(3):571-579. (PMID: 28555422)
Thromb Res. 2018 May;165:95-100. (PMID: 29605752)
Thromb Res. 2017 Aug;156:105-108. (PMID: 28624717)
Clin Neurol Neurosurg. 2015 Jul;134:55-9. (PMID: 25942630)
World Neurosurg. 2018 Jul;115:e723-e730. (PMID: 29715571)
Diagnostics (Basel). 2022 Nov 25;12(12):. (PMID: 36552961)
J Neurooncol. 2014 Feb;116(3):585-91. (PMID: 24414135)
J Neurosurg. 2019 Jan 4;132(1):10-21. (PMID: 30611138)
World Neurosurg. 2015 Jun;83(6):957-64. (PMID: 25943986)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Support Care Cancer. 2022 Jul;30(7):6063-6069. (PMID: 35419733)
PLoS Med. 2012;9(7):e1001275. (PMID: 22859911)
J Neurooncol. 2017 Mar;132(1):35-44. (PMID: 28102487)
J Thromb Haemost. 2022 Jul;20(7):1665-1673. (PMID: 35460331)
Haematologica. 2006 Aug;91(8):1046-51. (PMID: 16885044)
World Neurosurg. 2022 Aug;164:e619-e628. (PMID: 35589036)
Neurology. 2022 Jan 18;98(3):e260-e266. (PMID: 34795049)
Biomolecules. 2022 Feb 04;12(2):. (PMID: 35204760)
ESMO Open. 2020 May;5(3):e000647. (PMID: 32424065)
تواريخ الأحداث: Date Created: 20240620 Date Completed: 20240620 Latest Revision: 20240625
رمز التحديث: 20240625
مُعرف محوري في PubMed: PMC11189257
DOI: 10.1371/journal.pone.0304682
PMID: 38900739
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0304682